Difference between revisions of "Osocimab (BAY-1213790)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "www.ncbi.nlm.nih.gov/pubmed" to "pubmed.ncbi.nlm.nih.gov") |
m |
||
Line 5: | Line 5: | ||
===[[Venous thromboembolism]]=== | ===[[Venous thromboembolism]]=== | ||
# '''FOXTROT:''' Weitz JI, Bauersachs R, Becker B, Berkowitz SD, Freitas MCS, Lassen MR, Metzig C, Raskob GE. Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial. JAMA. 2020 Jan 14;323(2):130-139. [https://jamanetwork.com/journals/jama/article-abstract/2758600 link to original article] [https://pubmed.ncbi.nlm.nih.gov/31935028 PubMed] | # '''FOXTROT:''' Weitz JI, Bauersachs R, Becker B, Berkowitz SD, Freitas MCS, Lassen MR, Metzig C, Raskob GE. Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial. JAMA. 2020 Jan 14;323(2):130-139. [https://jamanetwork.com/journals/jama/article-abstract/2758600 link to original article] [https://pubmed.ncbi.nlm.nih.gov/31935028 PubMed] | ||
+ | |||
+ | ==Also known as== | ||
+ | *'''Code name:''' BAY 1213790 | ||
[[Category:Drugs]] | [[Category:Drugs]] |
Revision as of 14:04, 16 December 2020
Mechanism of action
Anti-Factor XIa antibody
Preliminary data
Venous thromboembolism
- FOXTROT: Weitz JI, Bauersachs R, Becker B, Berkowitz SD, Freitas MCS, Lassen MR, Metzig C, Raskob GE. Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial. JAMA. 2020 Jan 14;323(2):130-139. link to original article PubMed
Also known as
- Code name: BAY 1213790